

1 **High 3-hydroxybutyrate concentrations in the placenta-** 2 **produced amniotic fluid in the human uterus**

3 Takumi Satoh ^{1*}, Takeo Shibata², Emi Takata ², Masahiro Takakura ², Jia Han ³ and Sohsuke
4 Yamada ³

5 ¹ Department of Antiaging Food Research, School of Bioscience and Biotechnology, Tokyo
6 University of Technology, 1404-1 Katakura, Hachioji 192-0982, Japan., ² Department of
7 Obstetrics and Gynecology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan,
8 ³ Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Uchinada,
9 Ishikawa 920-0293, Japan.

10 *Corresponding author: E-mail: satotkm@stf.teu.ac.jp; Tel.: +81-90-6681-3367

11 **Key words**

12 3-hydroxybutyrate, ketone bodies, HMG-CoA synthase, placenta, amniotic fluid

13 **HIGHLIGHTS**

14 3-Hydroxybutyrate concentrations are high in the amniotic fluid in the human uterus.

15 The chorionic plate of the placenta highly expresses 3-hydroxy-3-methylglutaryl-CoA synthase 2.

16 Human fetuses may be supplied with 3HB for brain development through the amniotic fluid.

17 **ABSTRACT**

18 In this study, we report first high concentrations of a ketone body, 3-hydroxybutyrate (3HB) in
19 the amniotic fluid in humans. Although 3HB concentrations in the maternal blood are
20 approximately 0.1, those in the amniotic fluid are approximately 0.6 mM. High placental 3HB
21 production is potentially key for producing and maintaining high 3HB levels in the amniotic
22 fluid. The rate-limiting enzyme, mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 2
23 (HMGCS2), is highly expressed in the cells of the chorionic plate and responsible for 3HB
24 production. Therefore, high HMGCS2 expression maintenance is supposed to be pivotal for
25 maintaining the 3HB supply for the human fetus. Here, we propose that humans display two
26 pathways, an amniotic fluid- and another umbilical vein-mediated, for supplying 3HB to the
27 human fetus. These supply pathways are supposedly essential for human brain development
28 during the late phase of pregnancy.

29 Graphical abstract: Human fetuses are supported by 3HB from the amniotic fluid for their brain
30 development.

31 Abbreviations: 3-hydroxy-3-methylglutaryl-CoA synthase 2, HMGCS2; 3-hydroxybutyrate, 3HB

32 **Introduction**

33 Ketone bodies, composed of 3-hydroxybutyrate (3HB), acetoacetate, and acetone, are fatty acid-
34 derived energy substrates with supposed roles during starvation [1-2]. 3HB is produced through
35 fatty acid oxidative metabolism in the mitochondria and used as an energy substrate for
36 mitochondrial metabolism [3,4]. 3HB serves energy production in the mitochondria, affecting
37 human health in various ways. 3HB allows for higher ATP production than glucose as 3HB could
38 be fully oxidized [3-4]. In addition, 3HB induces various positive effects in humans [5-9].

39 Glucose and a ketone body (3hydroxybutyrate: 3HB) uptakes of the brain have been measured 48
40 years ago, taking samples from an aborted human fetus (28 weeks of gestation) and culturing for
41 several hours at the organ level. 3HB and glucose accounted for 60% and 40%of the energy,
42 respectively, providing direct evidence of the human fetal brain preferentially using 3HB as an
43 energy source [10]. The human brain can rapidly grow using an energy supply of a “main-3HB
44 and sub-glucose” system. At least, up to late pregnancy, the human brain could use 3HB as a fuel
45 [10,11]

46 Certain cells of endoderm origin, such as those of the gut, liver, and placenta, exhibit high
47 HMGCS2 expression, continuously producing 3HB both at the luminal and tissue sides [12-17].
48 For example, gut epithelial cells, with high HMGCS2 expression, could activate stem cell
49 population expansion by releasing 3HB into the tissue side of the ring structure [12,13]. In
50 particular, HMGCS2 is reportedly involved in anti-tumor effects in colorectal cancer [14,15].
51 Therefore, we suspect that a distinctive HMGCS2-related 3HB production system might exist in
52 the human placenta [16,17]. We also suppose that several 3HB supplying systems could be
53 installed in the human placenta for supplying 3HB to the human fetus.

54 3HB concentrations in the human and rat fetus are reportedly significantly high compared with
55 those in adults [10,11,18]. The human fetus certainly depends on 3HB as a main energy source.
56 One possible pathway is villi trophoblast→ umbilical vein → fetus, proposed by Muneta et al
57 (2016) [11]. However, we suspected the existence of an alternative pathway to supply 3HB to the
58 fetus.

59 **Methods and materials**

60 *Participants and 3HB measurements*

61 We involved nine healthy pregnant women in the study who had a cesarean section (C-section) in
62 full-term, without any abnormal glucose tolerance or gestational diabetes mellitus. 3HB levels
63 were measured in the umbilical vein, umbilical artery, amniotic fluid, and maternal blood.
64 Maternal blood was drawn the day before the C-section. Umbilical venous blood and umbilical
65 arterial blood were collected at C-section. The whole blood samples of maternal blood, umbilical
66 venous blood, and umbilical arterial were used for the 3HB measurements. We quickly collected
67 the amniotic fluid after the artificial rupture of the membrane at the time of the C-section with as
68 little maternal blood as possible. The amniotic fluid was centrifuged at 3000 G for 20 minutes to

69 remove fetal and maternal cells and blood, and the supernatant was used for 3HB measurements
70 using Precision Exceed III (Abbott).

71 *Histopathology and immunohistochemistry*

72 Histopathology and immunohistochemistry were performed as described previously[19,20]. The
73 paraffin-embedded human placenta samples were provided by the Kanazawa Medical University
74 (Ishikawa, Japan). The paraffin-embedded dissected placenta samples for histological
75 examinations were cut systematically in sequential 4- μ m-thick longitudinal sections using a
76 sliding microtome (Leica SM2010R, Leica Microsystems, Wetzlar, Germany). For the
77 histological analyses of the large intestine, we captured and merged images of hematoxylin and
78 eosin or HMGCS2 immunohistochemistry sections using the NanoZoomer Digital Pathology
79 Virtual Slide Viewer software program (Hamamatsu Photonics Corp., Hamamatsu, Japan).

80 HMGCS2 immunohistochemistry staining was performed using an HMGCS2 mouse monoclonal
81 antibody (SANTA CRUZ, sc-393256). The procedure was as follows: (1) deparaffinization and
82 rehydration; (2) 0.5% H_2O_2 blocking for 10 minutes at room temperature; (3) heating (95°C) in
83 an epitope retrieval buffer (pH6.0, with citric acid) for 10 minutes then cooling down for 30
84 minutes at room temperature; (4) primary antibody incubation overnight at 4°C (dilution: 1:500);
85 (5) secondary antibody (Histofine Simple Stain MAX-PO424152) staining for 30 minutes at room
86 temperature; (6) 3,3'-diaminobenzidine (Histofine Simple Stain SAB-PO425011) imaging and
87 hematoxylin counterstaining. For the HMGCS2 immunohistochemistry, we used human liver
88 cells as a positive control.

89 *Statistical analyses*

90 The data are represented as the mean \pm standard deviation. For statistical analyses, we calculated
91 the P-values according to the Mann–Whitney U test to compare the two groups.

92 *Ethical considerations*

93 The present study was conducted in compliance with the ethical principles of the Declaration of
94 Helsinki (Note of Clarification added at the 2004 World Medical Association General Assembly
95 in Tokyo), Japan's Act on the Protection of Personal Information, and with reference to the
96 Ministerial Ordinance on Good Clinical Practice for Drugs (Ordinance of Ministry of Health and
97 Welfare No.28 of March 27, 1997) and the Ethical Guidelines for Epidemiological Research
98 established by Japan's Ministry of Health, Labour and Welfare, and Ministry of Education,
99 Culture, Sports, Science and Technology. Concerning the 3HB measurements, this study was
100 approved by the Institutional Review Board at the Kanazawa Medical University (IRB #I747) and
101 written informed consent was obtained from all study participants. In the case of the HMGCS2
102 immunohistochemistry, our institution did not require any ethical approval for reporting
103 individual cases or case series.

104 **Results**

105 *Participant characteristics:*

106 The average age of the nine participants enrolled in this study was 37.3 ± 4.2 years. The
107 average week of C-section was 37.1 ± 0.3 . The indications for the C-section were repeated
108 cesarean birth (seven patients), prior myomectomies (one patient), and breech presentation (one
109 patient). Not all pregnant women were obese or underweight (body mass index [BMI]: $25.3 \pm$
110 3.0). No patients had any pregnancy-related complications (Table 1).

111 *HB measurements:*

112 We measured the 3HB concentrations in the amniotic fluid, umbilical vein, umbilical artery, and
113 maternal blood (Figure 1). The 3HB concentrations in the amniotic fluid were significantly higher
114 than those in the maternal blood (0.56 ± 0.2 vs. 0.12 ± 0.04 mM, $p = 0.003$, Mann–Whitney U
115 test). In addition, those in the umbilical vein (0.43 ± 0.31 , $p = 0.027$, Mann–Whitney U test)
116 and artery (0.42 ± 0.26 , $p = 0.045$, Mann–Whitney U test) were also higher than those in the
117 maternal blood.

118 *Case:*

119 We observed HMGCS2 expression in the placenta right after delivery (Figure 2). Although we
120 had supposed that HMGCS2 would be expressed in the trophoblast of the villi, the expression
121 was significant but not particularly potent. We discovered that the most potent tissue was the
122 chorionic plate and chorioamniotic membrane, supposedly releasing 3HB into the amniotic fluid.

123 **Discussion**

124 *Two ketone body supply pathways from the placenta*

125 Placenta is one of the most important 3HB suppliers of the human fetus during late pregnancy
126 [11,15]. Since most energy substrates are devoted to the development of the brain during late
127 pregnancy, placental 3HB production should be dedicated to fetal brain development. The
128 placenta exhibits two cell populations that produce 3HB for the fetus: placental villi and the
129 chorionic plate. We present an overview of 3HB flow in Figure 3.

130 **Declaration of competing interest**

131 The authors declare that they have no known competing financial interests or personal
132 relationships that could have appeared to influence the work reported in this study.

133 **Acknowledgments**

134 The authors thank Mr Takashi Tsujino for creating the graphical design for the Graphical
135 Abstract.

136 **REFERENCES**

- 137 1. Buono R. and Longo V.D. Starvation, stress resistance, and cancer. Trends Endocrinol.
138 Metab. 29 (2018), pp 271-280

- 139 2. Cahill G.F. Jr Fuel metabolism in starvation. *Annu. Rev. Nutr.* 26 (2006), pp 1-22
- 140 3. Campisi J. et al From discoveries in ageing research to therapeutics for healthy ageing.
141 *Nature* 571 (2019), pp 183-192
- 142 4. Kolb H. et al. Ketone bodies: from enemy to friend and guardian angel. *BMC Med.*
143 19(2021),13
- 144 5. Shippy D.C. et al. β -Hydroxybutyrate inhibits inflammasome activation to attenuate
145 Alzheimer's disease pathology. *J. Neuroinflammation* 17 (2020), p 280
- 146 6. Wang Z. et al. β -hydroxybutyrate improves cognitive impairment caused by chronic
147 cerebral hypoperfusion via amelioration of neuroinflammation and blood-brain barrier
148 damage. *Brain Res. Bull.* 193 (2023), pp 117-130
- 149 7. Yao A. et al. On the nutritional and therapeutic effects of ketone body D- β
150 hydroxybutyrate. *Appl. Microbiol. Biotechnol.* 105 (2021), pp 6229-6243
- 151 8. Murray A.J. et al. Novel ketone diet enhances physical and cognitive performance.
152 *FASEB J.* 30 (2016), pp 4021-4032
- 153 9. Newman J.C. and Verdin E. β -Hydroxybutyrate: a Signaling Metabolite. *Annu. Rev.*
154 *Nutr.* 37 (2017), pp 51-76
- 155 10. Adam P.A., et al Oxidation of glucose and D-B-OH-butyrate by the early human fetal
156 brain. *Acta Paediatr. Scand.* 64 (1975), pp 17-24
- 157 11. Muneta T., et al. "Ketone body elevation in placenta, umbilical cord, newborn and
158 mother in normal deliver. *Glycative Stress Res.* 3 (2016), pp 133-140
- 159 12. Cheng C.W. et al. Ketone body signaling mediates intestinal stem cell homeostasis and
160 adaptation to diet. *Cell* 178 (2019), pp 1115-1131.e15
- 161 13. Cheng Y.Y., et al. Metabolic changes associated with cardiomyocyte dedifferentiation
162 enable adult mammalian cardiac regeneration. *Circulation* 146 (2022), pp 1950-1967
- 163 14. Zou K., et al. Potential role of HMGCS2 in tumor angiogenesis in colorectal cancer and
164 its potential use as a diagnostic marker. *Can. J. Gastroenterol. Hepatol.* 2019 (2019), p
165 8348967
- 166 15. Camarero N., et al. Ketogenic HMGCS2 Is a c-Myc target gene expressed in
167 differentiated cells of human colonic epithelium and down-regulated in colon cancer.
168 *Mol. Cancer Res.* 4 (2006), pp 645-653
- 169 16. Cullingford T.E., et al. CoA lyase and detection of the corresponding mRNA and of those
170 encoding the remaining enzymes comprising the ketogenic 3-hydroxy-3methylglutaryl-
171 CoA cycle in central nervous system of suckling rat. *Biochem. J.* 329 (1998), pp 373-381
- 172 17. Chong D., et al Neonatal ketone body elevation regulates postnatal heart development by
173 promoting cardiomyocyte mitochondrial maturation and metabolic reprogramming. *Cell*
174 *Discov.* 8 (2022), p 106

- 175 18. Lockwood E.A. and Bailey E. The course of ketosis and the activity of key enzymes of
176 ketogenesis and ketone-body utilization during development of the postnatal rat.
177 Biochem. J. 124 (1971), pp 249-254
- 178 19. Han J., et al. Zonanol protected liver from methionine- and choline-deficient DietInduced
179 nonalcoholic fatty liver disease in a mouse model. Nutrients 13 (2021), p 3455
- 180 20. Yamada S., et al Marine hydroquinone zonanol prevents inflammation and apoptosis in
181 dextran sulfate sodium-induced mice ulcerative colitis. PLOS ONE 19 (2014), p
182 ppe113509

183

184 **Figure legends**

185 Figure 1: 3HB concentrations in various tissues. We compared the 3HB levels of (A) amniotic
186 fluid vs. maternal blood, (B) umbilical vein vs. maternal blood, and (C) artery vs. maternal blood
187 using the Mann–Whitney U test. The circles indicate amniotic fluid or umbilical vein or umbilical
188 artery. The triangles indicate maternal blood. **: $p < 0.01$; * : $p < 0.05$

189 Figure 2: HMGCS2 expression in the placenta. HMGCS2 expression was examined in the human
190 placenta using immunohistochemistry right after delivery. Note that the human placenta displays
191 two 3HB producers, villi and the chorionic plate to supply 3HB to the umbilical vein and
192 amniotic fluid, respectively.


193 Figure 3: Basic 3HB flow from the placenta to the human fetus. Two potential 3HB delivery
194 pathways exist from the placenta to the human fetus:


195 Pathway 1: Chorionic plate → amniotic fluid → small intestine → fetus

196 Pathway 2: Placental villi trophoblast → umbilical vein → fetus

197 Note that pathway 1 is a novel finding of this study.










Table 1 Patients Characteristics

| Patients | Gravidity | Parity | Week of Delivery | Height (cm) | Body Weight (Kg) | BMI | Indication of C-section | Mode of Conception | Complications of Pregnancy |
|-----------|-----------|--------|------------------|-------------|------------------|------|-------------------------|------------------------|----------------------------|
| Patient 1 | 2 | 1 | 37 | 160.5 | 58.5 | 22.7 | Repeat Cesarean Birth | Natural Pregnancy | None |
| Patient 2 | 2 | 0 | 38 | 162 | 71.9 | 27.4 | Prior Myomectomies | Natural Pregnancy | None |
| Patient 3 | 2 | 1 | 37 | 160.1 | 62.8 | 24.5 | Repeat Cesarean Birth | Natural Pregnancy | None |
| Patient 4 | 2 | 1 | 37 | 157 | 71.4 | 29 | Repeat Cesarean Birth | Natural Pregnancy | None |
| Patient 5 | 4 | 1 | 37 | 169 | 70.6 | 24.7 | Repeat Cesarean Birth | Natural Pregnancy | None |
| Patient 6 | 3 | 2 | 37 | 153 | 70.1 | 29.9 | Repeat Cesarean Birth | Natural Pregnancy | None |
| Patient 7 | 4 | 3 | 37 | 161 | 53.6 | 20.7 | Repeat Cesarean Birth | Natural Pregnancy | None |
| Patient 8 | 4 | 2 | 37 | 166 | 67.7 | 24.6 | Repeat Cesarean Birth | Natural Pregnancy | None |
| Patient 9 | 2 | 1 | 37 | 162 | 64 | 24.4 | Breech Presentation | In vitro fertilization | None |